Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Abstract

In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y₁₂ inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).

Keywords

Affiliated Institutions

• KU Leuven BE
• Leipzig Heart Institute DE
• Clinical Research Institute US
• Canadian VIGOUR Centre CA
• Bristol-Myers Squibb (United States) US
• Hospital Israelita Albert Einstein BR
• National Scientific Center "M.D. Strazhesko Institute of Cardiology" UA
• Cardiovascular Research Foundation US
• Vivantes Klinikum DE
• Pirogov Russian National Research Medical University RU
• University of Toronto CA
• Uppsala University SE
• Carol Davila University of Medicine and Pharmacy RO
• Duke University US
• Icahn School of Medicine at Mount Sinai US
• Instituto de Neurología Cognitiva AR
• University of Sheffield GB
• Grochowski Hospital PL
• University of Alberta CA

Related Publications